Literature DB >> 18794039

Use/misuse of over-the-counter medications and associated adverse drug events among HIV-infected patients.

Elizabeth Ajuoga1, Sujit S Sansgiry, Caroline Ngo, Rosa F Yeh.   

Abstract

BACKGROUND: Self-medication practices and polypharmacy are common among human immunodeficiency virus (HIV)-infected patients. Inappropriate use of over-the-counter (OTC) medications potentiates the risk for drug misuse and adverse drug events (ADEs).
OBJECTIVES: To investigate use and misuse of OTC medications in HIV-infected patients and determine related ADEs.
METHODS: A nonexperimental cross-sectional field study design was used. Study subjects were HIV-infected patients from a local HIV clinic in Houston, TX. Information on subject demographics, OTC medication use, and ADEs experienced were obtained using combined self-administered questionnaire and personal interview techniques. Misuse was divided into 3 categories: strength/frequency misuse, length misuse, and condition misuse. Data were analyzed using descriptive and Chi-square analyses.
RESULTS: A total of 215 completed surveys were obtained, with a net response rate of 63.6%. The mean (+/-SD) age of the respondents was 45 (+/-8.32) years and 69% were males. Analgesics/antipyretics (64.2%) were the most commonly used OTC medications of which nonsteroidal agents accounted for the greatest proportion (38.4%). Of the respondents, 80 (37.2%) misused OTC medications. The highest incidence occurred in length misuse (46.3%), followed by strength/frequency misuse (45.6%), and condition misuse (8.1%). Categories of misuse overlapped in 30 cases (20.1%). Thirty-six (16.7%) participants experienced at least one or more ADEs related to OTC medication use/misuse. Occurrence of ADEs was significantly higher in patients who misused OTC medications compared with those who did not (P < .05).
CONCLUSIONS: Analgesics/antipyretics were the most commonly used OTC medications by HIV-infected patients. The incidence of misuse and ADEs associated with OTC medications were documented with the sample. Keeping in mind the limitations of study design, our findings suggest that misuse of OTC medications in HIV-infected patients may increase the incidence of ADEs experienced.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794039     DOI: 10.1016/j.sapharm.2007.08.001

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  6 in total

1.  A qualitative study about self-medication in the community among market vendors in Fuzhou, China.

Authors:  Yi Wen; Eli Lieber; Dai Wan; Yuanhao Hong
Journal:  Health Soc Care Community       Date:  2011-06-08

2.  Views and experiences of healthcare professionals towards the use of African traditional, complementary and alternative medicines among patients with HIV infection: the case of eThekwini health district, South Africa.

Authors:  Manimbulu Nlooto
Journal:  BMC Complement Altern Med       Date:  2015-06-06       Impact factor: 3.659

Review 3.  The next therapeutic challenge in HIV: polypharmacy.

Authors:  E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

4.  Over-the-counter medicine abuse - a review of the literature.

Authors:  Richard J Cooper
Journal:  J Subst Use       Date:  2011-10-03

5.  Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals.

Authors:  Amy C Justice; Kirsha S Gordon; Melissa Skanderson; Eva Jennifer Edelman; Kathleen M Akgün; Cynthia L Gibert; Vincent Lo Re; David Rimland; Julie A Womack; Christina M Wyatt; Janet P Tate
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

6.  Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Côte d'Ivoire, West Africa: A cross-sectional study.

Authors:  Mariam Mama Djima; Didier Koumavi Ekouevi; Jean-Pierre Gregoire; Boris Tchounga; Patrick Ahuatchi Coffie; Viet-Thi Tran; Franck Y Touré; Jocelyne Moisan
Journal:  PLoS One       Date:  2019-09-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.